Jamie Dipietro
Urology · Fresno, CANPI 1740477850
Payments from drug & device makers
Across 355 payments — averaging $43.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Axonics, Inc.$1K
- AbbVie$1K
- Valencia Technologies Corporation$876
- Sumitomo Pharma America, Inc.$724
- Astellas Pharma US Inc$641
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$2,35015%
- Travel & lodging$3,50722%
- Food & beverage$9,67062%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 60 | $7,071 |
| Axonics, Inc. | 26 | $1,391 |
| AbbVie(2 entities) | 54 | $1,249 |
| Valencia Technologies Corporation | 5 | $876 |
| Sumitomo Pharma America, Inc. | 44 | $724 |
| Astellas Pharma US Inc | 35 | $641 |
| Teleflex LLC | 3 | $467 |
| Ferring Pharmaceuticals Inc. | 15 | $320 |
| Boston Scientific | 5 | $316 |
| Therapeuticsmd, Inc. | 24 | $248 |
| Urovant Sciences Inc | 19 | $247 |
| Endo Pharmaceuticals Inc. | 3 | $194 |
| Uromedica, Incorporated | 1 | $192 |
| Bluewind Medical | 3 | $173 |
| Antares Pharma, Inc. | 8 | $170 |
| Urogen Pharma, Inc. | 7 | $160 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
| Johnson & Johnson | 5 | $136 |
| Contura, Inc. | 1 | $130 |
| Tempus AI, Inc | 3 | $82 |
| Merck | 4 | $78 |
| Olympus America Inc. | 3 | $74 |
| Coloplast | 3 | $67 |
| Halozyme Inc | 3 | $62 |
| Dendreon Pharmaceuticals LLC | 3 | $54 |
| Progenics Pharmaceuticals, Inc. | 2 | $52 |
| Tolmar Pharmaceuticals, Inc. | 2 | $38 |
| Bayer | 2 | $38 |
| Profound Medical Corp. | 1 | $27 |
| Tolmar, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Palette Life Sciences, Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
| Myovant Sciences Inc. | 1 | $17 |
| Millicent US Inc | 1 | $17 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $14 |
| Rochester Medical Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$4,387
- Bulkamid$905
- eCoin Device Kit$809
- Axonics r-SNM System$665
- INTERSTIM ICON$586
- ALTAVIVA$388
- Barrigel$350
- BOTOX$273
- ProACT$192
- XIAFLEX$157
- Erleada$149
- REVI$130
- IMVEXXY$125
- GEMTESA$118
- GENERAL PELVIC ORGAN PROLAPSE$111
- FIRMAGON$109
- Solesta$103
- ADVANTAGE FIT$102
How this compares
$15,617 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 130 | $120,775 |
| GemtesaVibegron | 123 | $112,049 |
| PremarinEstrogens, Conjugated | 25 | $13,405 |
| Estradiol | 97 | $4,624 |
| Methenamine Hippurate | 24 | $2,069 |
| Desmopressin Acetate | 42 | $1,914 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,340 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $1,336 |
| Bethanechol Chloride | 17 | $904 |
| Solifenacin Succinate | 33 | $862 |
| Finasteride | 42 | $812 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $776 |
| Tamsulosin Hcl | 62 | $750 |
| Cephalexin | 55 | $731 |
| Dutasteride | 22 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $641 | $120,775130 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $724 | $112,049123 claims |
| PfizerPremarin | $18 | $13,40525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.
Other urology in Fresno
- William SchiffFresno$315K
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.